All lobbying filings

LMH STRATEGIC SOLUTIONS

Lobbying for IONIS PHARMACEUTICALS, INC. · Biotechnology company.

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 18, 2025

Income

$20,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 1

ALANNA TEMME

Previously held: Legislative Director, U.S. Representative Jon Porter

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the implementation of H.R.5547/S.476 - Maintaining Investments in New Innovation Act and H.R.7384 - Creating Hope Reauthorization Act of 2024. Pediatric Review Reauthorization. H.R.946 - ORPHAN Cures Act. H.R.1509/S.752 - Accelerating Kids Access to Care Act of 2025.

Bills named in this filing 6

H.R. 5547
Maintaining Investments in New Innovation Act
S. 476
Maintaining Investments in New Innovation Act
H.R. 7384
Creating Hope Reauthorization Act of 2024
H.R. 946
ORPHAN Cures Act
H.R. 1509
Accelerating Kids’ Access to Care Act of 2025
S. 752
Accelerating Kids’ Access to Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.